Advertisement
Research
Synaptic dysfunction contributes to cognitive impairment in Alzheimer’s disease and may be countered by increased intake of nutrients that target brain phospholipid metabolism. In this study, we explored wheth...
Alzheimer's Research & Therapy 2017 9:51
Published on: 26 July 2017
Research
The Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers Aβ1–42, t-tau, and p-tau181 overlap with other diseases. New tau modifications or epitopes, such as the non-phosphorylated tau fraction (p-taurel)...
Alzheimer's Research & Therapy 2017 9:49
Published on: 14 July 2017
Research
CAD-31 is an Alzheimer’s disease (AD) drug candidate that was selected on the basis of its ability to stimulate the replication of human embryonic stem cell-derived neural precursor cells as well as in APPswe/...
Alzheimer's Research & Therapy 2017 9:50
Published on: 14 July 2017
Research
This study sought to evaluate gender and APOE genotype-related differences in the concentrations of cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) and cerebrovascular injury across the life spa...
Alzheimer's Research & Therapy 2017 9:48
Published on: 3 July 2017
Research
Longitudinal studies of dementia with Lewy bodies (DLB) are rare. Clinically, DLB is usually considered to worsen into Alzheimer’s disease (AD). The aim of our study was to compare the rate of the cognitive de...
Alzheimer's Research & Therapy 2017 9:47
Published on: 27 June 2017
Research
The use of neurotrophic factors to treat Alzheimer’s disease (AD) is hindered by their blood–brain barrier impermeability, short half-life, and severe side effects. Peptide 021 (P021) is a neurotrophic/neuroge...
Alzheimer's Research & Therapy 2017 9:45
Published on: 27 June 2017
Research
The original paper Self-Administered Gerocognitive Examination (SAGE) is a valid and reliable cognitive assessment tool used to identify individuals with mild cognitive impairment (MCI) or early dementia. We e...
Alzheimer's Research & Therapy 2017 9:44
Published on: 27 June 2017
Research
Finding ways to reverse or prevent the consequences of pathogenic tau in the brain is of considerable importance for treatment of Alzheimer’s disease and other tauopathies. Immunotherapy against tau has shown ...
Alzheimer's Research & Therapy 2017 9:46
Published on: 27 June 2017
Research
Hyperhomocysteinemia is a risk factor for cognitive decline and dementia, including Alzheimer disease (AD). Homocysteine (Hcy) is a sulfur-containing amino acid and metabolite of the methionine pathway. The in...
Alzheimer's Research & Therapy 2017 9:43
Published on: 17 June 2017
Review
A major challenge to our understanding of the molecular mechanisms of Alzheimer’s disease (AD) has been the lack of physiologically relevant in vitro models which capture the precise patient genome, in the cel...
Alzheimer's Research & Therapy 2017 9:42
Published on: 13 June 2017
Research article
β-Amyloid peptide (Aβ) oligomers are initial factors used to induce Alzheimer’s disease (AD) development, and Aβ monomers have normal physiological function. The antibodies or vaccines against Aβ monomers have...
Alzheimer's Research & Therapy 2017 9:41
Published on: 7 June 2017
Research
Spaced retrieval training (SRT) is a nonpharmacological intervention for mild cognitive impairment (MCI) and dementia that trains the learning and retention of target information by recalling it over increasin...
Alzheimer's Research & Therapy 2017 9:39
Published on: 6 June 2017
Research
The pathophysiology of neurodegeneration is complex. Its diagnosis requires an early identification of sequential changes in several hallmarks in the brains of affected subjects. The presence of brain patholog...
Alzheimer's Research & Therapy 2017 9:40
Published on: 6 June 2017
Research
Pyroglutamylation of truncated Aβ peptides, which is catalysed by enzyme glutaminyl cyclase (QC), generates pE-Aβ species with enhanced aggregation propensities and resistance to most amino-peptidases and endo...
Alzheimer's Research & Therapy 2017 9:38
Published on: 6 June 2017
Research
A lot of attention has been paid to the relationship of blood pressure and dementia because epidemiological research has reported conflicting evidence. Observational data has shown that midlife hypertension is...
Alzheimer's Research & Therapy 2017 9:37
Published on: 31 May 2017
Research
The complexity of medication therapy in older adults with multiple comorbidities often leads to inappropriate prescribing. Drugs with anticholinergic properties are of particular interest because many are not ...
Alzheimer's Research & Therapy 2017 9:36
Published on: 23 May 2017
Review
Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiol...
Alzheimer's Research & Therapy 2017 9:35
Published on: 4 May 2017
Research
Our understanding of the molecular mechanisms underlying Alzheimer’s disease (AD) remains incomplete. Previous studies have revealed that genetic factors provide a significant contribution to the pathogenesis ...
Alzheimer's Research & Therapy 2017 9:29
Published on: 27 April 2017
Research
Safety warnings from health authorities are currently intended to limit the use of antipsychotics (APs) in dementia-related conditions to treat neuropsychiatric symptoms, such as disturbing and/or delusional b...
Alzheimer's Research & Therapy 2017 9:34
Published on: 26 April 2017
Research
The relative performance of semi-quantitative amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) markers in diagnosing Alzheimer’s disease (AD) and predicting the cognitive evolution of p...
Alzheimer's Research & Therapy 2017 9:32
Published on: 26 April 2017
Research
Aggregated amyloid-β peptide 1–42 (Aβ42), derived from the cellular amyloid precursor protein, is one of the pathological hallmarks of Alzheimer’s disease (AD). Although active immunization against Aβ42 peptid...
Alzheimer's Research & Therapy 2017 9:30
Published on: 26 April 2017
Research
Prior work suggests that some but not all antihypertensive treatments may benefit cognition and risk for Alzheimer’s disease, independent of stroke. Angiotensin II receptor blockers (ARBs) have been highlighte...
Alzheimer's Research & Therapy 2017 9:33
Published on: 26 April 2017
Review
Insulin resistance (IR) has previously been associated with an increased risk of developing Alzheimer’s disease (AD), although the relationship between IR and AD is not yet clear. Here, we examined the influen...
Alzheimer's Research & Therapy 2017 9:31
Published on: 26 April 2017
Research
Progressive supranuclear palsy (PSP) with a frontal presentation, characterized by cognitive deficits and behavioral changes, has been recognized as an early clinical picture, distinct from the classical so-ca...
Alzheimer's Research & Therapy 2017 9:28
Published on: 17 April 2017
Review
Cognitive, behavioural, and functional assessment is crucial in longitudinal studies of neurodegenerative dementias (NDD). Central issues, such as the definition of the study population (asymptomatic, at risk,...
Alzheimer's Research & Therapy 2017 9:27
Published on: 17 April 2017
